Novo Holdings A/S’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Novo Holdings A/S’s Portfolio KNTE Stock Details KNTE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-815,707	Closed	-$1.14M	–	41
2023 Q3	$1.14M	Hold	815,707	–	–	0.08%	39
2023 Q2	$2.47M	Hold	815,707	–	–	0.19%	39
2023 Q1	$5.1M	Hold	815,707	–	–	0.34%	42
2022 Q4	$4.98M	Hold	815,707	–	–	0.31%	42
2022 Q3	$9.75M	Hold	815,707	–	–	0.46%	38
2022 Q2	$10.3M	Buy	815,707 +191,471	+31%	+$1.78M	0.51%	36
2022 Q1	$7.03M	Buy	624,236 +71,108	+13%	+$783K	0.37%	40
2021 Q4	$9.8M	Buy	553,128 +54,600	+11%	+$1.15M	0.46%	31
2021 Q3	$11.5M	Buy	498,528 +198,528	+66%	+$4.32M	0.59%	28
2021 Q2	$6.98M	Hold	300,000	–	–	0.31%	44
2021 Q1	$9.35M	Hold	300,000	–	–	0.39%	34
2020 Q4	$11.9M	Buy	+300,000	New	+$12M	0.51%	31

Other funds holding KNTE

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

FCMV

Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

VVA

Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Novo Holdings A/S's KNTE Position: Q4 2023 in Review

Novo Holdings A/S sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q4 2023, closing a stake of 815,707 shares — an estimated $1.14M sold.

Novo Holdings A/S first reported a position in KNTE in Q4 2020 and held it in 12 quarters. The position peaked at $11.9M in Q4 2020. 62 funds tracked by Wall St. Rank hold KNTE as of Q4 2023.

Novo Holdings A/S reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Novo Holdings A/S sold 815,707 Kinnate Biopharma Inc. Common Stock shares in Q4 2023, an estimated $1.14M.
Novo Holdings A/S first reported a position in Kinnate Biopharma Inc. Common Stock in Q4 2020 and held it in 12 quarters.
Novo Holdings A/S's Kinnate Biopharma Inc. Common Stock position peaked at $11.9M in Q4 2020.
62 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q4 2023.

Based on Novo Holdings A/S's 13F filing for Q4 2023, filed 14 Feb 2024.